BioCentury
ARTICLE | Company News

CalciMedica, TorreyPines, CBR Institute for Biomedical Research deal

May 14, 2007 7:00 AM UTC

CalciMedica purchased TPTX's patent application covering uses of stromal interaction molecule-1 (STIM-1) for regulating Ca release-activated Ca ( CRAC) channels. CalciMedica also obtained NGX53187 and other preclinical compounds that inhibit CRAC channels and block the immune response. The company plans to develop the compounds to treat autoimmune and inflammatory diseases, including rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). TPTX, which said it sold the assets because they are outside the company's main focus of CNS disease, will receive equity in CalciMedica and is eligible for sublicensing fees, milestones and royalties. ...